ATE3865T1 - Hydantoinamine und deren pharmazeutische zusammensetzungen. - Google Patents

Hydantoinamine und deren pharmazeutische zusammensetzungen.

Info

Publication number
ATE3865T1
ATE3865T1 AT81300521T AT81300521T ATE3865T1 AT E3865 T1 ATE3865 T1 AT E3865T1 AT 81300521 T AT81300521 T AT 81300521T AT 81300521 T AT81300521 T AT 81300521T AT E3865 T1 ATE3865 T1 AT E3865T1
Authority
AT
Austria
Prior art keywords
compounds
analogs
amino
hydantoinamins
pharmaceutical compositions
Prior art date
Application number
AT81300521T
Other languages
English (en)
Inventor
Reinhard Sarges
Rodney Caughren Schnur
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Application granted granted Critical
Publication of ATE3865T1 publication Critical patent/ATE3865T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT81300521T 1980-02-12 1981-02-09 Hydantoinamine und deren pharmazeutische zusammensetzungen. ATE3865T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/120,944 US4248882A (en) 1980-02-12 1980-02-12 Treating diabetes-associated complications with hydantoin amines
EP81300521A EP0034063B1 (de) 1980-02-12 1981-02-09 Hydantoinamine und deren pharmazeutische Zusammensetzungen

Publications (1)

Publication Number Publication Date
ATE3865T1 true ATE3865T1 (de) 1983-07-15

Family

ID=22393428

Family Applications (1)

Application Number Title Priority Date Filing Date
AT81300521T ATE3865T1 (de) 1980-02-12 1981-02-09 Hydantoinamine und deren pharmazeutische zusammensetzungen.

Country Status (8)

Country Link
US (1) US4248882A (de)
EP (1) EP0034063B1 (de)
JP (1) JPS56127379A (de)
AT (1) ATE3865T1 (de)
DE (1) DE3160449D1 (de)
DK (1) DK156400C (de)
GR (1) GR73856B (de)
IE (1) IE50895B1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4490381A (en) * 1979-11-13 1984-12-25 Imperial Chemical Industries Plc 1'-Substituted spiro[imidazolidine-4,3'-indoline]2,2',5-triones
EP0065393B1 (de) * 1981-05-12 1984-12-27 Imperial Chemical Industries Plc Pyrrolderivate
US4556670A (en) * 1982-12-06 1985-12-03 Pfizer Inc. Spiro-3-hetero-azolones for treatment of diabetic complications
US4474967A (en) * 1983-04-27 1984-10-02 Pfizer Inc. 8-Deutero and 8-tritio-substituted derivatives of D-4S-6-fluoro-spiro-[chroman-4,4'-imidazolidine]-2',5'-dione
US4464380A (en) * 1983-05-25 1984-08-07 Pfizer Inc. Imidazolidinedione derivatives
DK277484A (da) * 1983-06-23 1984-12-24 Hoffmann La Roche Thiazolidinderivater
EP0172352B1 (de) * 1984-06-22 1990-08-29 Beecham Group Plc Wirksame Benzopyranverbindungen
US4680306A (en) * 1984-07-20 1987-07-14 Pfizer Inc. Sprio-imidazolones for treatment of diabetes complications
ATE37371T1 (de) * 1984-08-20 1988-10-15 Pfizer Verfahren zur herstellung asymmetrischer hydantoine.
US5340829A (en) * 1984-11-20 1994-08-23 Washington Research Foundation Immunoregulatory agents
US4966911A (en) * 1984-11-20 1990-10-30 Washington Research Foundation Immunoregulatory agents
JPH0772190B2 (ja) * 1985-02-26 1995-08-02 エーザイ株式会社 ヒダントイン誘導体
US4575507A (en) * 1985-05-29 1986-03-11 Pfizer Inc. Spiro-imidazolidines as aldose reductase inhibitors and their pharmaceutical use
US4762839A (en) * 1985-06-06 1988-08-09 Tanabe Seiyaku Co., Ltd. Quinazolinone copmpounds useful for the prophyloxis and treatment of diabetic complications
JPS63126881A (ja) * 1986-11-14 1988-05-30 Sanwa Kagaku Kenkyusho Co Ltd ヒダントイン誘導体、その塩、これらの製法並びに該化合物を有効成分とする糖尿病合併症の予防及び治療剤
JPS63132889A (ja) * 1986-11-21 1988-06-04 Tanabe Seiyaku Co Ltd キナゾリノン誘導体
MX12896A (es) * 1987-09-04 1993-06-01 Pfizer Procedimiento para preparar un compuesto de espiro-heteroazolonas
US4952694A (en) * 1988-07-27 1990-08-28 Pfizer Inc. Novel resolution process for racemic spiro-hydantoins
EP0536119A4 (en) * 1989-02-10 1993-08-04 Washington Research Foundation Immunoregulatory agents
JP2678499B2 (ja) * 1989-08-09 1997-11-17 日本臓器製薬 株式会社 ***毒素低下剤
JPH03215435A (ja) * 1990-01-12 1991-09-20 Sanwa Kagaku Kenkyusho Co Ltd アルドース還元酵素阻害剤を主成分とする潰瘍治療剤
EP1375485B1 (de) * 2001-04-05 2011-04-20 Nissan Chemical Industries, Ltd. Verfahren zur herstellung von 7-chinolinyl-3,5-dihydroxyhept-6-enoat
US7795203B2 (en) * 2002-09-30 2010-09-14 Babizhayev Mark A Method for topical treatment of eye disease and composition and device for said treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1135915B (de) * 1961-06-29 1962-09-06 Asta Werke Ag Chem Fab Verfahren zur Herstellung neuer, antikonvulsiv wirksamer Spirohydantoine
US3534037A (en) * 1968-05-10 1970-10-13 Smithkline Corp Spiro-(imidazolidine and pyrimidine-quinoline and cyclopropa(c)quinoline) compounds
US3821383A (en) * 1972-07-10 1974-06-28 Ayerst Mckenna & Harrison Compositions for and a method of treating diabetic complications
US4117230A (en) * 1976-10-18 1978-09-26 Pfizer Inc. Hydantoin derivatives as therapeutic agents
US4177282A (en) * 1977-05-23 1979-12-04 Pfizer Inc. Hydantoin therapeutic agents
US4130714A (en) * 1977-05-23 1978-12-19 Pfizer Inc. Hydantoin therapeutic agents
US4176185A (en) * 1979-01-22 1979-11-27 Pfizer Inc. Spiro-quinolylhydantoins
US4181729A (en) * 1979-03-21 1980-01-01 Pfizer Inc. Phenyl or phenoxy substituted spiro-imidazolidinedione derivatives

Also Published As

Publication number Publication date
DE3160449D1 (en) 1983-07-28
JPS6237636B2 (de) 1987-08-13
EP0034063A1 (de) 1981-08-19
DK56581A (da) 1981-08-13
IE810261L (en) 1981-08-12
US4248882A (en) 1981-02-03
DK156400B (da) 1989-08-14
JPS56127379A (en) 1981-10-06
IE50895B1 (en) 1986-08-06
EP0034063B1 (de) 1983-06-22
DK156400C (da) 1990-01-08
GR73856B (de) 1984-05-08

Similar Documents

Publication Publication Date Title
ATE3865T1 (de) Hydantoinamine und deren pharmazeutische zusammensetzungen.
SE7906949L (sv) Nya spiro-oxazolidindioner
NO890259D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive etylfenoksyacetamider.
IE790088L (en) Thienohydantoin derivatives
CO4930267A1 (es) Composiciones que contienen cisteina de n acetilo utiles en el tratamiento de heridas cronicas
AU581442B2 (en) 2-substituted-1, 3-propylidenediphosphonate derivatives, the process for their preparation and pharmaceutical compositions containing them
KR920017655A (ko) 상처의 치료를 촉진시키기 위한 약학 조성물
SE7909439L (sv) Spiro-polycykliska imidazolidindionderivat
ES2089136T3 (es) Tratamiento de enfermedades inflamatorias con la ayuda de derivados 15-ceto-prostaglandinas.
AU5917390A (en) Pharmaceutical composition for topic use for the therapeutical treatment of capillary fragility
BR9611276A (pt) Composto formulação farmacêutica processo para tratamento ou profilaxia de doenças ou condições de seres humanos e uso de um composto
DE59010302D1 (de) R-(-)-1-(5-Hydroxyhexyl)-3-methyl-7-propylxanthin, Verfahren zu dessen Herstellung und diese Verbindung enthaltende Arzneimittel
DK0378146T3 (da) Polyamin-derivater som antineoplastiske midler
KR910018028A (ko) 15- 데히드록시-16-옥소프로스타글란딘 화합물에 의한 생화학적 치료
IL70690A (en) 5-(2-alkoxyphenyl)thiazolidinediones and pharmaceutical compositions containing them
FI884911A (fi) Laekemedel, i dessa saosom aktiva aemnen befintliga fosforin innehaollande 2-isoxazoliner och isoxazoler samt foerfarande foer framstaellning av dessa heterocykliska foereningar.
SE8002244L (sv) Nytt 1alfa,25-dihydroxi-cholekalciferolderivat, sett for framstellning samt anvendning derav som lekemedel och farmaceutiska kompositioner inehallande denna forening
IE800672L (en) Spiro-quinolone hydantoins
ITMI911845A1 (it) Uso dei derivati dell'acido benzimidazolin-2-oxo-1-carbossilico.
MX9302929A (es) Derivados de tetrahidro y perhidroisoquinolina y medios terapeuticos que los contienen.
NO165399C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive (5r,6s)-6-((r)-1-hydroksyetyl)-penem-derivater.
AU4246189A (en) Medicament for the treatment of diseases caused by retroviruses
ATE109454T1 (de) Catecholaminester.
IT1243368B (it) Uso del bendazac e dei suoi sali farmaceuticamente accettabili

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee